FIELD: biotechnology.
SUBSTANCE: invention relates to a humanized monoclonal antibody against Aβ, as well as to a nucleic acid molecule encoding a monoclonal antibody, an expression vector, a host cell for the production of a monoclonal antibody, a method for the production of a monoclonal antibody, the use of a monoclonal antibody, a drug for prevention or treatment of a disease, where the disease includes amyloidosis selected from secondary amyloidosis and age-related amyloidosis and a neurological disease, which is Alzheimer’s disease, and to a kit for detection of Aβ expression.
EFFECT: proposed humanized monoclonal antibody can inhibit polymerization of Aβ monomers, protect nerve cells from Aβ toxicity, and exert certain impact on improvement of cognitive abilities for training and memorizing in mice with Alzheimer’s dementia model.
13 cl, 13 ex, 12 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODIES TO LIGAND OF RECEPTOR TYROSINE KINASE 3 SIMILAR TO PRODUCT OF PROTOONCOGENE OF FELINE SARCOMA VIRUS (FMS) OF MCDONOUGH (FLT3L) STRAIN AND OPTIONS OF THEIR USE FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | 2019 |
|
RU2788128C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| HETERODIMERIC BISPECIFIC ANTIBODY AGAINST TNFα/AGAINST IL-17A, SIMILAR BY STRUCTURE TO NATURAL ANTIBODY, AND ITS PRODUCTION METHOD | 2019 |
|
RU2781816C1 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
